Non-dopaminergic drug treatment of Parkinson’s disease

Bibliography

• FOLEY P, RIEDERER P: Pathogenesis and preclinical course of Parkinson's disease. J. Neural. Transm. (1999) (Suppl. 56):31–74.
   Google Scholar
• BRAAK H, BRAAK E, YILMAZER D, DE VOS RA, JANSENEN, BOHL J: New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. J. Neural. Transm. (1996) (Suppl. 48):1–6.
   Google Scholar
• BRAAK H, BRAAK E, YILMAZER D, SCHULTZ C, DE VOSRA, JANSEN EN: Mgral and extranigral pathology in Parkinson's disease. J Neural. Transm. (1995) (Suppl. 46):15–31.
   Google Scholar
• KUHN W, MULLER T, NASTOS I, POEHLAU D: Theneuroimmune hypothesis in Parkinson's disease. Rev. Neurosci. (1997) 8(1):29–34
   PubMedGoogle Scholar
• HIRSCH EC, HUNOT S, DAMIER P, FAUCHEUX B: Glialcells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol (1998) 44(3 Suppl. 1):S115–S120.
   Google Scholar
• PRZUNTEK H, MULLER T: Clinical efficacy of budipine inParkinson's disease. J Neural. Transm. (1999) (Suppl. 56):75–82.
   Google Scholar
• PRZUNTEK H: Non -dop aminergic therapy in Parkin-son's disease. J Neurol. (2000) 247 (Suppl. 2):I119–1124.
   Google Scholar
• BEAL MF: Excitotoxicity and nitric oxide in Parkin-son's disease pathogenesis. Ann. Neurol. (1998) 44(3 Suppl. 1):S110–S114.
   Google Scholar
• GERLACH M, BLUM-DEGEN D, LAN J, RIEDERER P: Nitricoxide in the pathogenesis of Parkinson's disease. Adv. Neurol (1999) 80:239–245.
   PubMedGoogle Scholar
• CHASE TN, OH JD: Striatal mechanisms andpathogenesis of parkinsonian signs and motor complications. Ann. Neurol. (2000) 47(4 Suppl. 1):S122–S129.
   Google Scholar
• ELTZE M: Multiple mechanisms of action: the pharma-cological profile of budipine. J Neural Transm. (1999) (Suppl. 56):83–105.
   Google Scholar
• MENGE HG, BRAND U: [Summarizing descrip tion of the pharmacology of budipine, a new 4,4- diphenyl-piperidine derivative used in Parkinson therapy (author's trans1)]. Arzneimittelforschung (1982) 32 (2):85–98.
   PubMedGoogle Scholar
• SCHAEFER H, HACKMACK G, EISTETTER K, KRUGER U, MENGE HG, KLOSA J: [Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4- diphenyl-piperidines]. Arzneimittelforschung (1984) 34 (3):233–240.
   PubMedGoogle Scholar
• JACKISCH R, HUANG HY, REIMANN W, LIMBERGER N: Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J. Pharmacol. Exp. Ther. (1993) 264 (2):889–898.
   PubMedGoogle Scholar
• JACKISCH R, KRUCHEN A, SAUERMANN W, HERTTING G, FEUERSTEIN TJ: The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur. j Pharmacol. (1994) 264 (2):207–211.
   PubMedGoogle Scholar
• KLOCKGETHER T, WULLNER U, STEINBACH JP, PETERSEN V, TURSKI L, LOSCHMANN PA: Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur. j Pharmacol (1996) 301 (1-3):67–73.
   PubMedGoogle Scholar
• KLOCKGETHER T, JACOBSEN P, LOSCHMANN PA, TURSKI L: The antiparkinsonian agent budipine is an N-m e th y 1 -D-asp ar tate antagonist. J. Neural Transm. Park Dis. Dement. Sect. (1993) 5(2):101–106.
   PubMedGoogle Scholar
• KORNHUBER J, HERR B, THOME J, RIEDERER P: The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm. (1995) (Suppl. 46):131–137.
   Google Scholar
• MULLER T, KRUGER R, PRZNUNTEK H, KUHN W: Inhibi-tion of tumor necrosis factor-a and interleukin-6 synthesis by budipine. In: 4th Congress of the European Society for Clinical Neuropharmacology, International Proceedings Division Monduzzi Editore SPA Amos D Korczyn (Ed.) (1997):103–106.
   Google Scholar
• PRZUNTEK H, RUSS H, HENNING K, PINDUR U: The protective effect of 1-tert.buty1-4,4- diphenyl-piperidine against the nigrostriatal neurodegenera-tion caused by 1 -methy1-4-pheny1-1,2,3,6-tetrahydropyridine. Life Sci. (1985) 37 (13) :1195–1200.
   Google Scholar
• PRZUNTEK H, RUSS H: Budip in e and the MPTP bindingsite [letter]. Lancet (1985) 2(8445):35–36.
   PubMedGoogle Scholar
• RUSS H, HENNING K, ECKHARDT H, PRZUNTEK H: The influence of N-methy1-4-pheny1-1,2,3,6- tetrahydropy-ridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat. Arzneimittelforschung (1985) 35 (2):481–482.
   PubMedGoogle Scholar
• SPIEKER S, LOSCHMANN P, JENTGENS C, BOOSE A, KLOCKGETHER T, DICHGANS J: Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin. Neuropharmacol (1995) 18 (3):266–272.
   PubMed Web of Science ®Google Scholar
• SPIEKER S, EISEBITT R, BREIT S et al.: Tremorlytic activity of budipine in Parkinson's disease. Clin. Neuropharmacol (1999) 22(2):115–119.
   PubMedGoogle Scholar
• JELLINGER K, BLIESATH H: Adjuvant treatment of Parkinson's disease with budipine: a double- blind trial versus placebo. J Neurol (1987) 234 (5):280–282.
   PubMedGoogle Scholar
• KOTTER R: Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol (1994) 44(2):163–196.
   PubMed Web of Science ®Google Scholar
• CHASE TN, OH JD, KONITSIOTIS S: Antiparkinsonianand antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol. (2000) 247 (Suppl. 2):1136–1142.
   Google Scholar
• FARR SA, FLOOD JF, MORLEY JE: The Effect ofCholinergic, GABAergic, Serotonergic and Glutamatergic Receptor Modulation on Posttrial Memory Processing in the Ilippocampus. Neurobiol. Learn. Mem. (2000) 73(2):150–167.
   PubMedGoogle Scholar
• KAWAHARA H, KAWAHARA Y, WESTERINK BH: The role of afferents to the locus coeruleus in the handling stress- induced increase in the release of noradrena-line in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur. J. Pharmacol. (2000) 387 (3):279–286.
   PubMedGoogle Scholar
• GRIFFITHS MR, COOPER AJ, BARBER DJ, MITCHELL IJ: Pharmacological mechanisms mediating phencyclidine-induced apoptosis of striatopallidal neurons: the roles of glutamate, dopamine, acetylcho-line and co r tico s ter o ids . Brain Res. (2000) 855 (1) :1–10.
   PubMedGoogle Scholar
• CHASE TN, OH JD, BLANCHET PJ: Neostriatal mechanisms in Parkinson's disease. Neurology (1998) 51(2 Suppl. 2):530–535.
   Google Scholar
• LANGE KW, KORNHUBER J, RIEDERER P: Dopamine/glutamate interactions in Parkinson's disease. NeuroscL Biobehav. Rev. (1997) 21 (0393–400.
   PubMedGoogle Scholar
• HURLEY MJ, MASH DC, JENNER P: Adenosine A(2A) receptor mRNA expression in Parkinson's disease. NeuroscL Lett. (2000) 291 (1):54–58.
   PubMedGoogle Scholar
• JENNER P: Pathophysiology and biochemistry ofdyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. (2000) 247 (Suppl. 2):1143–1150.
   Google Scholar
• ZENG BY, PEARCE RK, MACKENZIE GM, JENNER P: Alterations in preproenkephalin and adenosine-2a receptor mRNA but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur. J. NeuroscL (2000) 12(3):1096–1104.
   PubMedGoogle Scholar
• MULLER T, KUHN W, PRZUNTEK H: An tich olin er gika. In: Neuro-Psychopharmaka. Riederer P, Laux G (Eds.) Springer-Verlag, Wien, New York (1999) 2 (2):79–84.
   Google Scholar
• FAHN S, BURKE R, STERN Y: An timuscarinic drugs in the treatment of movement disorders. Prog. Brain Res. (1990) 84:389–397.
   PubMedGoogle Scholar
• PONDAL M, DEL SER T, BERMEJO F: Anticholinergic therapy and dementia in patients with Parkinson's disease. J Neurol. (1996) 243 (7):543–546.
   PubMedGoogle Scholar
• VAN SPAENDONCK KP, BERGER HJ, HORSTINK MW, BUYTENHUIJS EL, COOLS AR: Impaired cognitive shifting in parkinsonian patients on anticholinergic therapy. Neuropsychologia (1993) 31 (4):407–411.
   PubMedGoogle Scholar
• DE SMET Y, RUBERG M, SERDARU M, DUBOIS B, LHERMITTE F, AGID Y: Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol. Neurosurg. Psychiatry (1982) 45(12):1161–1164.
   PubMed Web of Science ®Google Scholar
• PARKES JD, CALVER DM, ZILKHA KJ, KNILL-JONES RP: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet (1970) 1 (7640:259–262.
   PubMedGoogle Scholar
• SCHWAB RS, ENGLAND AC, Jr., POSKANZER DC, YOUNGRR: Arnantadine in the treatment of Parkinson's disease. JAMA (1969) 208 (7):1168–1170.
   Google Scholar
• SCHWAB RS, ENGLAND AC, Jr:. Arnantadine HCL(Symmetrel) and its relation to Izvo-Dopa in the treatment of Parkinson's disease. Trans. Am. Neurol Assoc. (1969) 94:85–90.
   Google Scholar
• FACTOR SA, MOLHO ES: Transient benefit ofamantadine in Parkinson's disease: the facts about the myth. Mov. Disord. (1999) 14(3):515–517.
   PubMed Web of Science ®Google Scholar
• DANIELCZYK W: Twenty-five years of amantadinetherapy in Parkinson's disease. J Neural Transm. (1995) (Suppl. 46)399–405.
   Google Scholar
• SHANNON KM, GOETZ CG, CARROLL VS, TANNER CM,KLAWANS HL: Amantadine and motor fluctuations in chronic Parkinson's disease. Clin. Neuropharmacol. (1987) 10(6):522–526.
   PubMedGoogle Scholar
• MULLER T, KUHN W, QUACK G, PRZUNTEK H: Intrave-nous application of amantadine and antiparkinsonian efficacy in Parkinsonian patients. J Neural Transm. (1995) (Suppl. 46):407–413.
   Google Scholar
• BENNETT VL, JUORIO AV, LI XM: Possible newmechanism for the antiparkinsonian effect of amantadine [letter]. J. Psychiatry Neurosci. (1999) 24 (1):52–53.
   PubMedGoogle Scholar
• DANYSZ W, PARSONS CG, KORNHUBER J, SCHMIDT WJ,QUACK G: Arninoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. NeuroscL Biobehav. Rev. (1997) 21 (4):455–468.
   PubMed Web of Science ®Google Scholar
• KORNHUBER J, WELLER M: Psychotogenicity andN-methyl-D-aspartate receptor antagonism: implica-tions for neuroprotective pharmacotherapy. Psychiatry (1997) 41 (2):135–144.
   Web of Science ®Google Scholar
• STOOF JC, BOOIJ J, DRUKARCH B: Arnantadine asN-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? an. Neurol Neurosurg. (1992) 94 (Suppl. S4–S6).
   Google Scholar
• WESEMANN W, DETTE-WILDENHAHN G, FELLEHNER H:In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson. J Neural Transm. (1979) 44 (4) :263–285.
   PubMedGoogle Scholar
• GRELAK RP, CLARK R, STUMP JM, VERNIER VG:Arnantadine-dopamine interaction: possible mode of action in Parkinsonism. Science (1970) 169(940:203–204.
   PubMedGoogle Scholar
• JACKISCH R, LINK T, NEUFANG B, KOCH R: Studies onthe mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic proper-ties. Arch. Int. Pharmacodyn. Ther. (1992) 320:21–42.
   PubMedGoogle Scholar
• KOSTIC VS, SVETEL M, STERNIC N, DRAGASEVIC N,PRZEDBORSKI S: Theophylline increases 'on' time in advanced parkinsonian patients. Neurology (1999) 52 (9):1916.
   PubMedGoogle Scholar
• UITTI RJ, RAJPUT AH, AHLSKOG JE et al.: Arnantadinetreatment is an independent predictor of improved survival in Parkinson's disease. Neurology (1996) 46 (6):1551–1556.
   PubMedGoogle Scholar
• FAHN S: Is levodopa toxic? Neurology (1996) 47(6 Suppl.3):S184–S195.
   Google Scholar
• AGID Y: Izvodopa: is toxicity a myth? Neurology (1998)50 (4):858–863.
   PubMedGoogle Scholar
• AGID Y, AHLSKOG E, ALBANESE A et al.: Izvodop a in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. (1999) 14(6):911–913.
   PubMedGoogle Scholar
• FAHN S: Controversies in the therapy of Parkinson's disease. Adv. Neurol. (1996) 69:477–486.
   PubMedGoogle Scholar
• DODEL RC, EGGERT KM, SINGER MS, EICHHORN TE, POGARELL O, OERTEL WH: Costs of drug treatment in Parkinson's disease. Mov. Disord. (1998) 13 (2) :249–254.
   PubMed Web of Science ®Google Scholar
• GRACE AA, BUNNEY BS: The control of firing pattern in nigral dopamine neurons: burst firing. j Neurosci. (1984) 4(11):2877–2890.
   PubMedGoogle Scholar
• GRACE AA, BUNNEY BS: The control of firing pattern in nigral dopamine neurons: single spike firing. J. NeuroscL (1984) 4(10:2866–2876.
   PubMedGoogle Scholar
• MULLER T, EISING EG, REINERS C, PRZUNTEK H, JACOB M, KUHN W: 24123IFiodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal presynaptic degeneration? Nucl. Med. Commun. (1997) 18(12):1115–1121.
   Google Scholar
• EKESBO A, RYDIN E, TORSTENSON R, SYDOW O, LAENGSTROM B, TEDROFF J: Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology (1999) 52(0:120–125.
   PubMedGoogle Scholar
• MELAMED E, HEFTI F, WURTMAN RJ: Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann. Neurol. (1980) 8 (6):558–563.
   PubMed Web of Science ®Google Scholar
• WACHTEL SR, ABERCROMBIE ED: L-3,4 - dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem. (1994) 63(1):108–117.
   PubMedGoogle Scholar
• NG LK, CHASE TN, COLBURN RW, KOPIN IJ: L-dopa in Parkinsonism. A possible mechanism of action. Neurology (1972) 22 (7):688–696.
   Google Scholar
• HORNYKIEWICZ O: Biochemical aspects of Parkinson's disease. Neurology (1998) 51(2 Suppl. 2):S2–S9.
   Google Scholar
• COLOSIMO C: The rise and fall of tolcap one. J Neurol.(1999) 246(10):880–882.
   PubMedGoogle Scholar
• MULLER T, WOITALLA D, SCHULZ D, PETERS S, KUHN W,PRZUNTEK H: Tolcap one increases maximum concen-tration of levodopa. J. Neural Transm. (2000) 107(0:113–119.
   PubMedGoogle Scholar
• QUIGLEY EM: Gastrointestinal dysfunction in Parkin-son's disease. Semin. Neurol (1996) 16(3):245–250.
   PubMedGoogle Scholar
• PRZUNTEK H, WELZEL D, GERLACH M et al.: Early institu-tion of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm. Gen. Sect. (1996) 103(6):699–715.
   PubMed Web of Science ®Google Scholar
• RASCOL O, BROOKS DJ, KORCZYN AD, DE DEYN PP, CLARKE CE, LANG AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(201484–1491.
   Google Scholar
• RINNE UK, BRACCO F, CHOUZA C et al.: Early treatmentof Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs (1998) 55 (Suppl. 0:23–30.
   Google Scholar
• VERHAGEN ML, DEL DOTTO P, BLANCHET PJ, VAN DENMP, CHASE TN: Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids (1998) 14 (1-3):75–82.
   PubMedGoogle Scholar
• ADLER CH, STERN MB, VERNON G, HURTIG HI: Arnantadine in advanced Parkinson's disease: good use of an old drug [letter]. J. Neurol. (1997) 244 (5):336–337.
   PubMedGoogle Scholar
• VERHAGEN ML, DEL DOTTO P, LEPOOLE K, KONITSIOTISS, FANG J, CHASE TN: Arnantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol. (1999) 56(11):1383–1386.
   PubMedGoogle Scholar
• VERHAGEN ML, DEL DOTTO P, VAN DEN MP, FANG J, MOURADIAN MM, CHASE TN: Arnantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology (1998) 50(5):1323–1326.
   PubMed Web of Science ®Google Scholar
• RASCOL O: The pharmacological therapeutic manage-ment of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol. (2000) 247 (Suppl. 2):I151–1157.
   Google Scholar
• MERIMS D, ZIV I, DJALDETTI R, MELAMED E: Riluzole forlevodopa-induced dyskinesias in advanced Parkin-son's disease. Lancet (1999) 353 (9166):1764–1765.
   PubMedGoogle Scholar
• SPIEKER S, LOSCHMANN PA, KLOCKGETHER T: The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations. Mov. Disord. (1999) 14 (3):517–519.
   PubMed Web of Science ®Google Scholar
• MAERTENS DN, DELWAIDE PJ: Open pilot trial ofritanserin in parkinsonism. Clin. Neuropharmacol. (1986) 9(5):480–484.
   PubMedGoogle Scholar
• LINAZASORO G: Worsening of Parkinson's disease bycitalopram. Parkinsonism and Related Disorders (2000) 6 (2):111–114.
   PubMedGoogle Scholar
• DI ROCCO A, BRANNAN T, PRIKHOJAN A, YAHR MD: Sertraline induced parkinsonism. A case report and an in vivo study of the effect of sertraline on dopamine metabolism. J. Neural Transm. (1998) 105 (2-3):247–251.
   Google Scholar
• DURIF F, VIDAILHET M, BONNET AM, BUN J, AGID Y:Levodopa-induced dyskinesias are improved by fluoxetine. Neurology (1995) 45 (10):1855–1858.
   PubMedGoogle Scholar
• BONIFATI V, FABRIZIO E, CIPRIANI R, VANACORE N,MECO G: Buspirone in levodopa-induced dyskinesias. Neuropharmacol. (1994) 17(0:73–82.
   Google Scholar
• DURIF F: Treating and preventing levodopa-induceddyskinesias: current and future strategies. Drugs Aging (1999) 14(5):337–345.
   PubMedGoogle Scholar
• GHIKA J, TENNIS M, HOFFMAN E, SCHOENFELD D, GROWDON J: Idazoxan treatment in progressive supranuclear palsy. Neurology (1991) 41 (7):986–991.
   PubMed Web of Science ®Google Scholar
• GRONDIN R, TAHAR AH, DOAN VD, LADURE P, BEDARDPJ: Noradrenoceptor antagonism with idazoxan improves L-dop a-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch. PharmacoL (2000) 361 (2) :181–186.
   PubMedGoogle Scholar
• BEZARD E, BREFEL C, TISON F et al.: Effect of the a 2adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsy-chopharmacol Biol. Psychiatry (1999) 23 (7):1237–1246.
   PubMedGoogle Scholar
• HENRY B, FOX SH, PEGGS D, CROSSMAN AR, BROTCHIEJM: The a2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances antiparkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. MovDisord. (1999) 14(5)744–753.
   Google Scholar
• HERTEL P, NOMIKOS GG, SVENSSON TH: Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. Eur.J. Pharmacol. (1999) 371 (2-3):153–158.
   PubMedGoogle Scholar
• RASCOL O, BREFEL-COURBON C, BUN O: [Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients]. Therapie (1998) 53(1):43–48.
   PubMedGoogle Scholar
• CAREY RJ: Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci. (1991) 48(13):1303–1308.
   PubMedGoogle Scholar
• SANDYK R, SNIDER SR: Naloxone treatment ofL-dopa-induced dyskinesias in Parkinson's disease [letter]. Am. J. Psychiatry (1986) 143(0:118.
   PubMedGoogle Scholar
• CARPENTIER AF, BONNET AM, VIDAILHET M, AGID Y:Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology (1996) 46(6):1548–1551.
   PubMedGoogle Scholar
• MENDEZ JS, COTZIAS GC, MENA I, PAPAVASILIOU PS:Diphenylhydantoin. Blocking of levodopa effects. Arch. Neurol (1975) 32 (1):44–46.
   PubMedGoogle Scholar
• BLANCHET PJ, FANG J, HYLAND K, ARNOLD LA, MOURADIAN MM, CHASE TN: Short-term effects of high-dose 1713-estradiol in postmenopausal PD patients: a crossover study. Neurology (1999) 53 (1):91–95.
   PubMedGoogle Scholar
• VILLENEUVE A, LANGLIER P, BEDARD P: Estrogens, dopamine and dyskinesias. Can. Psychiatr. Assoc. J. (1978) 23 (1):68–70.
   PubMedGoogle Scholar
• GOMEZ-MANCILLA B, BEDARD PJ: Effect of nondopa-minergic drugs on L-dopa-induced dyskinesias in MPTP- treated monkeys. Clin. Neuropharmacol. (1993) 16 (5):418–427.
   PubMedGoogle Scholar
• PIERELLI F, ADIPIETRO A, SOLDATI G, FATTAPPOSTA F, POZZESSERE G, SCOPPETTA C: low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol. Scand. (1998) 97 (5):295–299.
   PubMed Web of Science ®Google Scholar
• MULLER T, WOITALLA D, SAFT C, KUHN W. Izvodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism and Related Disorders (2000) 6:171–173.
   PubMed Web of Science ®Google Scholar
• MILLER JW, SHUKITT-HALE B, VILLALOBOS-MOLINA R et al.: Effect of L-dopa and the catechol-0-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol (1997) 20(0:55–66.
   PubMedGoogle Scholar
• GORELL JM, JOHNSON CC, RYBICKI BA: Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data,1970 to 1990. Neurology (1994) 44 (10) :1865–1868.
   PubMedGoogle Scholar
• BEN SHLOMO Y, MARMOT MG: Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J. Neurol. Neurosurg. Psychiatry (1995) 58(3):293–299.
   PubMedGoogle Scholar
• CHAMBERS JC, MCGREGOR A, JEAN-MARIE J, KOONER JS: Acute hyperhomocysteinaemia and endothelial dysfunction [letter] [see comments]. Lancet (1998) 351 (9095):36–37.
   PubMed Web of Science ®Google Scholar
• ALLAIN P, LE BOUIL A, CORDILLET E, LE QUAY L, BAGHERI H, MONTASTRUC JL: Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology (1995) 16(3):527–529.
   PubMedGoogle Scholar
• KUHN W, ROEBROEK R, BLOM H, VAN OPPENRAAIJ D, MULLER T: Hyperhomocysteinaemia in Parkinson's disease [letter]. J Neurol. (1998) 245 (12):811–812.
   PubMedGoogle Scholar
• YASUI K, KOWA H, NAKASO K, TAKESHIMA T, NAKASHIMA K: Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology (2000) 55(3):437–440.
   PubMed Web of Science ®Google Scholar
• MULLER T, WERNE B, FOWLER B, KUHN W: Mgral endothelial dysfunction, homocysteine and Parkin-son's disease [letter]. Lancet (1999) 354(9173):126–127.
   PubMedGoogle Scholar
• LIU XX, WILSON K, CHARLTON CG: Effects of L-dopa treatment on methylation in mouse brain: implica-tions for the side effects of L-dopa. Life Sci. (2000) 66 (23):2277–2288.
   PubMedGoogle Scholar
• CHENG H, GOMES-TROLIN C, AQUILONIUS SM et al.: Levels of L-methionine 5-adenosyltransferase activity in erythrocytes and concentrations of 5-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp. Neurol. (1997) 145(2 Pt 0:580–585.
   Google Scholar
• FAUCHEUX BA, BONNET AM, AGID Y, HIRSCH EC: Blood vessels change in the mesencephalon of patients with Parkinson's disease [letter]. Lancet (1999) 353 (9157):981–982.
   PubMedGoogle Scholar
• COONEY CA, WISE CK, POIRIER LA, ALI SF: Metham-ph etamin e treatment affects blood and liver S-adenosylmethionine (SAM) in mice. Correlation with dopamine depletion in the striatum. Ann. NY Acad. Sci (1998) 844:191–200.
   Google Scholar
• STAMLER JS, OSBORNE JA, JARAKI O et al: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. OM. Invest. (1993) 91 (1):308–318.
   PubMedGoogle Scholar
• LIPTON SA, KIM WK, CHOI YB et al: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Nati Acad. Sci. USA (1997) 94(10:5923–5928.
   PubMedGoogle Scholar
• PARSONS RB, WARING RH, RAMSDEN DB, WILLIAMS AC. In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology (1998) 19 (4-5):599–603.
   PubMedGoogle Scholar
• RODRIGUEZ MC, OBESO JA, OLANOW CW: Subthalamic nucleus-mediated ex cito toxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. (1998) 44(3 Suppl. 1):S175–S188.
   Google Scholar
• LEES AJ: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's disease Research Group of the United Kingdom [see comments]. Br. Med. J. (1995) 311 (7020):1602–1607.
   PubMedGoogle Scholar
• OLANOW CW, MYLLYLA W, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology (1998) 51 (3):825–830.
   PubMedGoogle Scholar
• PRZUNTEK H, WELZEL D, BLUMNER E et al.: Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued [see comments]. Eur. J. OM. Pharmacol. (1992) 43 (0357–363.
   PubMedGoogle Scholar
• RINNE UK: [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy]. Nervenarzt (1999) 70 (Suppl. 1):S19–S25.
   Google Scholar
• HELY MA, MORRIS JG, TRAFICANTE R, REID WG, O'SULLIVAN DJ, WILLIAMSON PM: The Sydney multi-centre study of Parkinson's disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry (1999) 67 (3):300–307.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, NIETO FJ, KRUGER WD et al.: The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. (1997) 17(6):1157–1162.
   PubMed Web of Science ®Google Scholar
• NALLAMOTHU BK, FENDRICK AM, RUBENFIRE M, SAINT S, BANDEKAR RR, OMENN GS: Potential clinical and economic effects of homocyst(e)ine lowering. Arch. Intern. Med. (2000) 160 (22) :3406–3412.
   PubMedGoogle Scholar
• KORCZYN AD: Parkinson's disease: one disease entity or many? J. Neural Transm. (1999) (Suppl. 56):107–111.
   Google Scholar